Given the significant evidence for PGRN’s tight in vivo regulatory control and in light of recent diagnostic and therapeutic efforts aimed at modulating PGRN levels in patients (particularly, those with neurodegenerative disease), we present these data in an effort to optimize future work in these areas. Here, GRN is linked to neurodegenerative disease.